ANRO
Alto Neuroscience, Inc.NYSEHealthcare$21.68-7.39%ClosedMarket Cap: $692.6M
As of 2026-04-06
Valuation
P/E (TTM)
—
PEG
—
P/B
4.76
P/S
0.00
EV/EBITDA
-9.20
DCF Value
$5.91
FCF Yield
-7.2%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-48.2%
ROA
-34.2%
ROIC
-37.9%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $0.00 | -Infinity% | $-17.1M | $-16.2M | $-0.51 | — |
| FY 2025 | $0.00 | -Infinity% | $-66.4M | $-63.2M | $-2.19 | — |
| Q3 2025 | $0.00 | -Infinity% | $-15.0M | $-14.2M | $-0.52 | — |
| Q2 2025 | $0.00 | -Infinity% | $-18.7M | $-17.7M | $-0.65 | — |
| Q1 2025 | $0.00 | NaN% | $-15.7M | $-15.2M | $-0.56 | — |
| Q4 2024 | $0.00 | -Infinity% | $-17.0M | $-15.2M | $-0.56 | — |
| FY 2024 | $0.00 | -Infinity% | $-68.6M | $-61.4M | $-2.50 | — |
| Q3 2024 | $0.00 | NaN% | $-18.9M | $-16.8M | $-0.62 | — |
| Q2 2024 | $0.00 | NaN% | $-18.3M | $-16.0M | $-0.59 | — |
| Q1 2024 | $0.00 | -Infinity% | $-14.4M | $-13.4M | $-0.50 | — |
| Q4 2023 | $0.00 | -Infinity% | $-11.8M | $-11.2M | $-0.42 | — |
| FY 2023 | $0.00 | NaN% | $-37.8M | $-36.3M | $-1.35 | — |